{"subscriber":false,"subscribedOffers":{}}

Cookies Notification

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more.
×

Research Article

Precision medicine

Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis–Related Hospitalizations

Affiliations
  1. Lisa B. Feng ([email protected]) is senior director for policy and advocacy at the Cystic Fibrosis Foundation, in Bethesda, Maryland.
  2. Scott D. Grosse is a research economist at the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia.
  3. Ridgely Fisk Green is a Carter Consulting, Inc. contractor in the Office of Public Health Genomics, CDC.
  4. Aliza K. Fink is director of epidemiology at the Cystic Fibrosis Foundation.
  5. Gregory S. Sawicki is an assistant professor of pulmonology at Boston Children’s Hospital, in Massachusetts.
PUBLISHED:May 2018Free Accesshttps://doi.org/10.1377/hlthaff.2017.1554

References

  • 1 Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd Cet al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016;13(7):1173–9. Crossref, Medline, Google Scholar
  • 2 Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5. Crossref, Medline, Google Scholar
  • 3 Marson FAL, Bertuzzo CS, Ribeiro JD. Personalized or precision medicine? The example of cystic fibrosis. Front Pharmacol. 2017;8:390. Crossref, Medline, Google Scholar
  • 4 Martiniano SL, Sagel SD, Zemanick ET. Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr. 2016;28(3):312–7. Crossref, Medline, Google Scholar
  • 5 Paranjape SM, Mogayzel PJ Jr. Cystic fibrosis in the era of precision medicine. Paediatr Respir Rev. 2018;25:64–72. Medline, Google Scholar
  • 6 Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012;18(4):509–19. Crossref, Medline, Google Scholar
  • 7 Cystic Fibrosis Foundation. 2016 Patient Registry: annual data report [Internet]. Bethesda (MD): The Foundation; 2017 [cited 2018 Feb 26]. Available from: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Patient-Registry-Annual-Data-Report.pdf Google Scholar
  • 8 Vertex [Internet]. Boston (MA): Vertex; 2012. Press release, FDA approves KalydecoTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis; 2012 Jan 31 [cited 2018 Feb 26]. Available from: http://investors.vrtx.com/releasedetail.cfm?releaseid=644257 Google Scholar
  • 9 De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016;4(8):662–74. Crossref, Medline, Google Scholar
  • 10 Herper M. The most important new drug of 2012. Forbes [serial on the Internet]. 2012 Dec 27 [cited 2018 Feb 26]. Available from: https://www.forbes.com/sites/matthewherper/2012/12/27/the-most-important-new-drug-of-2012/#40ad3bfb3a6a Google Scholar
  • 11 Cystic Fibrosis Foundation. President Obama highlights cystic fibrosis in 2015 State of the Union address [Internet]. Bethesda (MD): Cystic Fibrosis Foundation; 2015 Jan 21 [cited 2018 Feb 26]. Available from: https://www.cff.org/News/News-Archive/2015/President-Obama-Highlights-Cystic-Fibrosis-in-2015-State-of-the-Union-Address/ Google Scholar
  • 12 Joyner MJ, Paneth N. Seven questions for personalized medicine. JAMA. 2015;314(10):999–1000. Crossref, Medline, Google Scholar
  • 13 Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek Pet al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72. Crossref, Medline, Google Scholar
  • 14 Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione Bet al. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015;13:93. Crossref, Medline, Google Scholar
  • 15 Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark Det al. Improvement in exercise duration, lung function, and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clin Sci (Lond). 2017;131(15):2037–45. Crossref, Medline, Google Scholar
  • 16 Suthoff ED, Bonafede M, Limone B, O’Callaghan L, Sawicki GS, Wagener JS. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. J Med Econ. 2016;19(9):845–51. Crossref, Medline, Google Scholar
  • 17 Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CAet al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and Cystic Fibrosis Patient Registry data. Am J Respir Crit Care Med. 2015;192(7):836–42. Crossref, Medline, Google Scholar
  • 18 Sawicki GS, Dasenbrook E, Fink AK, Schechter MS. Rate of uptake of ivacaftor use after U.S. Food and Drug Administration approval among patients enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Ann Am Thorac Soc. 2015;12(8):1146–52. Medline, Google Scholar
  • 19 Vertex [Internet]. Boston (MA): Vertex; 2017. Press release, FDA approves KALYDECO® (ivacaftor) for more than 600 people ages 2 and older with cystic fibrosis who have certain residual function mutations; 2017 Aug 1 [cited 2018 Feb 26]. Available from: http://investors.vrtx.com//releasedetail.cfm?ReleaseID=1035299 Google Scholar
  • 20 To access the appendix, click on the Details tab of the article online.
  • 21 Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280–8. Crossref, Medline, Google Scholar
  • 22 Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258–64. Crossref, Medline, Google Scholar
  • 23 Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren Ket al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017;166(8):537–46. Crossref, Medline, Google Scholar
  • 24 Corcoran A, Hickey N, Barry M, Usher C, McCullagh LM. Ivacaftor for cystic fibrosis: an evaluation of real world utilisation and expenditure in the Irish Healthcare Setting. Ir Med J. 2017;110(7):619. Medline, Google Scholar
  • 25 Hubert D, Dehillotte C, Munck A, David V, Baek J, Mely Let al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. J Cyst Fibros. 2018;17(1):89–95. Crossref, Medline, Google Scholar
  • 26 Clinical and Functional Translation of CFTR. Welcome to the CFTR2 website [Internet]. Baltimore (MD): Johns Hopkins University, CFTR2; c 2011 [cited 2018 Feb 26]. Available from: https://www.cftr2.org/mutations_history Google Scholar
  • 27 Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45–56. Crossref, Medline, Google Scholar
  • 28 Durmowicz AG, Lim R, Rogers H, Rosebraugh CJ, Chowdhury BA. The U.S. Food and Drug Administration’s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial. Ann Am Thorac Soc. 2018;15(1):1–2. Crossref, Medline, Google Scholar
  • 29 Cystic Fibrosis Foundation. FDA approves ivacaftor for 23 additional CFTR mutations [Internet]. Bethesda (MD): The Foundation; 2017 May 17 [cited 2018 Feb 26]. Available from: https://www.cff.org/News/News-Archive/2017/FDA-Approves-Ivacaftor-for-23-Additional-CFTR-Mutations/ Google Scholar
  • 30 Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NLet al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7. Crossref, Medline, Google Scholar
Loading Comments...